Understanding Your Scleritis Diagnosis
At a Glance
Scleritis is deep inflammation of the eye’s white outer wall that can cause severe pain and threaten vision. Prompt evaluation by an experienced ophthalmologist, often with a rheumatologist, helps identify related immune conditions and guide treatment with medicines that work throughout the body.
Being diagnosed with scleritis can feel overwhelming, especially when you are dealing with the intense, deep-seated pain that often defines this condition. Because scleritis is rare, you may find that many people—including some healthcare providers—are unfamiliar with it. Understanding the nature of this disease and how it differs from more common eye issues is the first step toward managing it effectively.
What is Scleritis?
Scleritis is a serious medical condition involving inflammation of the sclera, the tough, white outer wall of the eye [1]. Unlike a simple “red eye,” scleritis affects the deep, structural tissues of the eye globe [2].
The pain associated with scleritis is often described as a severe, “boring” ache that can spread to the forehead, jaw, or temple [3]. This pain is a physical signal of the intense inflammation occurring in the dense collagen of your eye [4]. Because the sclera holds the shape of the eye, inflammation here is considered potentially vision-threatening and requires prompt, specialized care [2].
Scleritis vs. Episcleritis
It is common for patients to confuse scleritis with episcleritis, a much more common and generally mild condition.
- Episcleritis is inflammation of the thin layer of tissue (the episclera) that sits on top of the white of the eye [5]. It usually causes redness and mild discomfort but rarely threatens vision and often clears up on its own [4].
- Scleritis involves the deeper, thicker layers. It is much more painful and does not resolve without medical treatment [1].
A key difference your doctor looks for is the involvement of deep blood vessels; in scleritis, these vessels do not “blanch” (turn white) when certain eye drops are applied, whereas they do in episcleritis [4].
How Rare is Scleritis?
Scleritis is considered a rare disease. Research indicates that its incidence (the number of new cases diagnosed each year) is between approximately 1.38 and 6.8 cases per 100,000 people [6][7].
Because it is uncommon, your local optometrist or general practitioner may see only a few cases in their entire career. This is why it is often necessary to see a specialist, such as a uveitis specialist or an ophthalmologist with experience in ocular inflammatory diseases, to ensure you receive the correct diagnosis and treatment plan [2].
The Emotional Impact
Receiving a diagnosis for a rare, painful, and potentially sight-threatening condition is a significant life event. It is normal to feel anxious, frustrated, or fearful. Studies have shown that the psychological burden of scleritis is real:
- Different studies show varying statistics depending on the group measured, with clinical anxiety or depression affecting roughly 9.3% to 21.6% of patients with scleritis [8].
- A broader review of ocular inflammatory diseases found that up to 35% of patients reported symptoms of anxiety [9].
- Higher levels of distress are often linked to the severity of the pain and concerns about how the disease might affect your vision or daily life [9][10].
Validating these feelings is a part of your care. Managing the emotional stress is just as important as managing the physical inflammation [11].
Prognosis and Treatment Goals
While scleritis is serious, it is manageable. The primary goal of treatment is to control the inflammation, protect your vision, and relieve your pain [2].
Most patients require systemic therapy—medication that works throughout the whole body—rather than just eye drops [12]. This is because scleritis is often linked to an underlying systemic (body-wide) inflammatory or autoimmune condition, such as rheumatoid arthritis or vasculitis [13]. In fact, about 43% of people with scleritis have an associated immune-mediated disease [13].
Your individualized treatment may involve:
- NSAIDs: Strong anti-inflammatory pills for milder cases [2].
- Corticosteroids: Often used to quickly bring severe inflammation under control [14].
- Immunomodulatory Therapy: If the disease is persistent, “steroid-sparing” medications may be used to keep the immune system in check over the long term [12].
- Biologic Therapies: Advanced medications that target specific parts of the immune system for difficult-to-treat cases [15].
With the right care team—often including both an ophthalmologist and a rheumatologist—patients can often achieve disease control (remission) and maintain their vision [16][17].
Helpful Definitions
- Anterior: The front part of the eye.
- Posterior: The back part of the eye, behind the visible surface.
- Necrotizing: Severe inflammation causing tissue thinning or damage.
- Systemic: Affecting the entire body, not just the eye.
- Immunosuppressant: A medication that calms an overactive immune system.
Common questions in this guide
What does a scleritis diagnosis mean?
What do anterior, posterior, and necrotizing scleritis mean?
How is scleritis different from episcleritis?
Could scleritis be related to another health condition?
What medicines are used to treat scleritis?
Who treats scleritis, and can treatment protect my vision?
How might a scleritis diagnosis affect my emotional health?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What type of scleritis do I have (anterior or posterior), and is it 'necrotizing'?
- 2.How much experience do you have treating scleritis, and do you work with a rheumatologist for systemic management?
- 3.Given my diagnosis, which specific blood tests or imaging do I need to look for underlying causes?
- 4.Since I am in significant pain, what is our immediate plan to manage the inflammation and the pain itself?
- 5.What is the goal for my vision, and what signs should I look for that my treatment needs to be adjusted?
- 6.How long do you expect I will need to be on systemic medications like steroids or immunosuppressants?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (17)
- 1
Ocular Pharmacology for Scleritis: Review of Treatment and a Practical Perspective.
Stem MS, Todorich B, Faia LJ
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2017; (33(4)):240-246 doi:10.1089/jop.2016.0127.
PMID: 28355124 - 2
Current Approach for the Diagnosis and Management of Noninfective Scleritis.
Dutta Majumder P, Agrawal R, McCluskey P, Biswas J
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; (10(2)):212-223 doi:10.1097/APO.0000000000000341.
PMID: 33290287 - 3
NODULAR POSTERIOR SCLERITIS: Clinico-Sonographic Characteristics and Proposed Diagnostic Criteria.
Agrawal R, Lavric A, Restori M, et al.
Retina (Philadelphia, Pa.) 2016; (36(2)):392-401 doi:10.1097/IAE.0000000000000699.
PMID: 26296144 - 4
Etanercept-associated episcleritis: a pediatric case report of a paradoxical adverse reaction and review of the literature.
Küçükali B, Gezgin Yıldırım D, Esmeray Şenol P, et al.
Clinical rheumatology 2024; (43(2)):799-808 doi:10.1007/s10067-023-06793-4.
PMID: 37845415 - 5
Clinical Correlates, Outcomes, and Predictors of Inflammatory Ocular Disease Associated with Rheumatoid Arthritis in the Biologic Era.
Caimmi C, Crowson CS, Smith WM, et al.
The Journal of rheumatology 2018; (45(5)):595-603 doi:10.3899/jrheum.170437.
PMID: 29449499 - 6
The Global Epidemiology of Scleritis: A Systematic Review and Meta-analysis.
Cifuentes-González C, Mejía-Salgado G, Rojas-Carabali W, et al.
American journal of ophthalmology 2025; (273()):13-32 doi:10.1016/j.ajo.2025.01.019.
PMID: 39892801 - 7
Incidence and Prevalence of Scleritis Subtypes and Associated Ocular Complications in the TriNetX Database.
Spangler MD, Marshall RF, Kirupaharan N, et al.
American journal of ophthalmology 2025; (277()):365-374 doi:10.1016/j.ajo.2025.05.028.
PMID: 40447245 - 8
The Association Between Mental Health Disorders and Non-Infectious Scleritis: A Prevalence Study and Review of the Literature.
Abdel-Aty A, Kombo N
European journal of ophthalmology 2022; (32(4)):1850-1856 doi:10.1177/11206721211067652.
PMID: 34913750 - 9
Anxiety and Depression among Patients with Uveitis and Ocular Inflammatory Disease at a Tertiary Center in Southern Thailand: Vision-Related Quality of Life, Sociodemographics, and Clinical Characteristics Associated.
Sittivarakul W, Wongkot P
Ocular immunology and inflammation 2019; (27(5)):731-742 doi:10.1080/09273948.2018.1484495.
PMID: 29969331 - 10
Incidence and Prevalence of Depression, Anxiety, and Suicidal Ideation in Patients with Uveitis and Scleritis in the TriNetX Database.
Agarwal R, Lee D, Mendez Bermudez I, Berkenstock MK
Ocular immunology and inflammation 2026; 1-9 doi:10.1080/09273948.2026.2633447.
PMID: 41824366 - 11
Evaluation and correlation analysis of ocular surface disorders and quality of life in autoimmune rheumatic diseases: a cross-sectional study.
Ren Y, Tian J, Shi W, et al.
BMC ophthalmology 2023; (23(1)):229 doi:10.1186/s12886-023-02959-5.
PMID: 37217899 - 12
Patterns of Non-Infectious Scleritis across a Tertiary Eye Care Network Using the Indigenously Developed Electronic Medical Record System-eyeSmart.
Murthy SI, Das AV, Kammari P, et al.
Ocular immunology and inflammation 2022; (30(7-8)):1733-1739 doi:10.1080/09273948.2021.1942497.
PMID: 34255594 - 13
Scleritis and Development of Immune-Mediated Disease: A Retrospective Chart Review.
Morrison T, Gottman M, Do T, et al.
The Journal of rheumatology 2024; (51(8)):825-830 doi:10.3899/jrheum.2023-0788.
PMID: 38302174 - 14
Clinical characteristics and efficacy of methotrexate in Japanese patients with noninfectious scleritis.
Hiyama T, Harada Y, Kiuchi Y
Japanese journal of ophthalmology 2021; (65(1)):97-106 doi:10.1007/s10384-020-00778-5.
PMID: 33107015 - 15
Management of noninfectious scleritis.
Abdel-Aty A, Gupta A, Del Priore L, Kombo N
Therapeutic advances in ophthalmology 2022; (14()):25158414211070879 doi:10.1177/25158414211070879.
PMID: 35083421 - 16
Remission of Non-Infectious Anterior Scleritis: Incidence and Predictive Factors.
Kempen JH, Pistilli M, Begum H, et al.
American journal of ophthalmology 2021; (223()):377-395 doi:10.1016/j.ajo.2019.03.024.
PMID: 30951689 - 17
Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study.
Sharma SM, Damato E, Hinchcliffe AE, et al.
The British journal of ophthalmology 2021; (105(9)):1256-1262 doi:10.1136/bjophthalmol-2018-312767.
PMID: 30862619
This page is for informational purposes only and does not constitute medical advice about scleritis. Your ophthalmologist and, when needed, rheumatologist can interpret your symptoms, tests, and treatment plan.
Get notified when new evidence is published on scleritis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.